Effect Of Invokana (canagliflozin ) Versus Januvia (sitagliptin) On Blood Glucose Levels, A1C, And Blood Pressure | Ahamed Munaser, PharmD Intern | RxEconsult
Menus

All Health Articles

Effect Of Invokana Versus Januvia On Blood Glucose Levels, A1C, And Blood Pressure Category: Diabetes by - June 10, 2016 | Views: 44251 | Likes: 0 | Comment: 1  

Side effects of Invokana versus Januvia

Side effect rates were similar in both Invokana (76.7%) and Januvia (77.5%) groups. Incidences of serious side effects were low for both groups. There were higher incidences of mycotic genital infections and osmotic diuresis with Invokana that led to one discontinuation of treatment. Low blood glucose (hypoglycemia) rates were similar in both groups.

Common Side Effects

Genital Mycotic Infection

  • Invokana (Males = 9.2%; Females = 15.3%)
  • Januvia (Males = 0.5%; Females = 4.3%)

Urinary Tract Infection

  • Invokana (4%)
  • Januvia (5.6%)

Pollakiuria

  • Invokana (1.6%)
  • Januvia (1.3%)

Polyuria

  • Invokana (0.8%)
  • Januvia (0%)

Postural Dizziness

  • Invokana (None)
  • Januvia (0.5%)

Orthostatic Hypotension

  • Invokana (0%)
  • Januvia (0.3%)

Serious Side Effects

Hypoglycemic Episode

  • Invokana (43.2%)
  • Januvia (40.7%)

Severe Hypoglycemic Episode

  • Invokana (4%)
  • Januvia (3.4%)

Conclusion

In conclusion, Invokana was found to provide a better improvement than Januvia in blood glucose, A1C, and body weight reduction. Invokana also reduced blood pressure better than Januvia. Although side effects were similar between Invokana and Januvia, Invokana was associated with increased genital infections in patients with type 2 diabetes on metformin and a sulfonylurea.

Join The Diabetes Education And Support Facebook Group

 

References

Invokana [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2015.

Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trialDiabetes Care. 2013;36(9):2508-2515. doi:10.2337/dc12-2491.

Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia. 2013;56:2582-2592. 

McCormack JP, Martin SA, Newman DH. Comment on Inzucchi et al. Management of Hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes care 2015;38: 140–149. Diabetes Care. 2015;38(9):e141–e142. doi:10.2337/dc15-0074.

FDA approves Invokana to treat type 2 diabetes. Accessed June 8, 2016. 

Chen MA, Medicine, Cardiology D of, et al. Digitalis toxicity: MedlinePlus medical encyclopedia. Accessed June 8, 2016.

Image courtesy of stockimages at FreeDigitalPhotos.net

 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2022 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap